Status:
COMPLETED
Intravitreal Conbercept After Vitrectomy
Lead Sponsor:
Tianjin Medical University Eye Hospital
Conditions:
Early Proliferative Diabetic Retinopathy
Eligibility:
All Genders
28-80 years
Phase:
EARLY_PHASE1
Brief Summary
To evaluate the safety and efficacy of intravitreal conbercept after vitrectomy for the management of early-stage proliferative diabetic retinopathy (PDR). Hypothesis: intravitreal conbercept therapy...
Detailed Description
The drug conbercept (an anti-vascular endothelial growth factors) was recently made available for management of early prolific diabetic retinopathy, but its safety and efficacy still require study. Th...
Eligibility Criteria
Inclusion
- We enrolled 50 eyes from 50 patients that were affected by VH as a consequence of early active PDR.
- Patients with non-clearing VH and fibrocellular proliferation without TRD who underwent PPV at Tianjin Medical University Eye Hospital were included in the study.
Exclusion
- A history of previous PPV;
- Severe intraoperative complications
- Postoperative silicone oil tamponade;
- Menstruation;
- Stroke, a thromboembolic event, or myocardial infarction in the previous
- months contraindicating the withdrawal of anti-platelet and anti-coagulant medications.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03426540
Start Date
January 1 2017
End Date
February 28 2019
Last Update
April 30 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.